CNTXContext Therapeutics Inc. Common Stock
0.5001USD+2.58%Mkt Cap: 45.95M $P/E: —3d ago
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody …
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap45.95M $
Enterprise Value5.00M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-36.12M $
Revenue/Share—
Last Price0.5001 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.19
PEG—
EV/EBITDA-0.10
EV/Revenue—
P/S—
P/B1.25
EPS (TTM)-0.51
EPS (Forward)-0.44
52W Range
0.43202% of range3.620
52W High3.620 USD
52W Low0.4320 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-59.73%
ROA-52.74%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-26.39M $
CapEx (TTM)2.03M $
FCF Margin—
FCF Yield-68.61%
Net Debt-42.75M $
Net Debt/EBITDA0.88
Balance Sheet
Debt/Equity0.00
Current Ratio5.81
Quick Ratio5.45
Book Value/Sh0.4150 USD
Cash/Share0.4680 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.251 USD
Upside (mean)+750.1%
Target Range2.000 USD – 6.000 USD
$2.000+750.1% to mean$6.000
# Analysts9
Ownership
Shares Out.91.88M
Float63.73M
Insiders1.57%
Institutions69.02%
Short Interest
Short Ratio2.4d
Short % Float7.32%
Short % Out.6.35%
Shares Short5.83M
Short (prev mo.)3.21M
Technical
SMA 500.6389 (-21.7%)
SMA 2001.678 (-70.2%)
Beta1.75
S&P 52W Chg18.16%
Avg Vol (30d)2.11M
Avg Vol (10d)2.06M
Technical Indicators
RSI (14)38.0
MACD-0.0776
MACD Signal-0.0936
MACD Hist.+0.0160
BB Upper0.6920 USD
BB Middle0.5543 USD
BB Lower0.4165 USD
BB Width49.70%
ATR (14)0.0615 USD
Vol Ratio (20d)0.99x